Cost-effectiveness of pneumococcal vaccines for adults in the United States.

ABSTRACT:

Introduction

In 2012, the Advisory Committee on Immunization Practices (ACIP) revised recommendations for adult pneumococcal vaccination to include a sequential regimen of 13-valent pneumococcal conjugate vaccine (PCV13) followed by 23-valent pneumococcal polysaccharide vaccine (PPSV23) for certain high-risk adults with immunocompromising conditions. This study, from a payer perspective, examined: (1) the cost-effectiveness of the new 2012 ACIP vaccine policy recommendation relative to the 1997 ACIP recommendation; (2) the cost-effectiveness of potential future pneumococcal vaccination policies; and (3) key assumptions that influence study results.

Methods

A static cohort model that incorporated costs, health outcomes, and quality-adjusted life-year (QALY) losses associated

SUBMITTER: Chen J 

PROVIDER: S-EPMC4003344 | biostudies-literature | 2014 Apr

REPOSITORIES: biostudies-literature